David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Science and Engineering Ethics 9 (1):59-71 (2003)
When the University of Toronto withdrew a contract it held with me in December 2000, it initiated a sequence of events that led to a public letter to the University from senior figures in the world psychopharmacology community protesting against the infringement of academic freedom involved and a first ever legal action, undertaked by this author, seeking redress for a violation of academic freedom. The issues of academic freedom surrounding this case have been intertwined with a debate about the possibility that the selective serotonin reuptake inhibitor (SSRI) group of antidepressants have the potential to trigger suicidality in a subgroup of patients. Whether the SSRIs do trigger suicidality or not, exploration of this issue has given rise to a number of worrying sets of observations. First, in my view, there is evidence that pharmaceutical companies have miscoded raw data on suicidal acts and suicidal ideation. Second, this author also maintains that there is a growing body of examples of ghostwriting of articles in the therapeutics domain. Many of the tensions evident in this case, therefore, can be linked to company abilities to keep clinical trial data out of the public domain — this is the point at which the pharmaceutical python gets a grip on academia.
|Keywords||hazards of drug treatment ghostwriting academic freedom|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
Vincent Norcia (2005). Intellectual Property and the Commercialization of Research and Development. Science and Engineering Ethics 11 (2):203-219.
Professor G. R. Evans & D. E. Packham (2003). Ethical Issues at the University-Industry Interface: A Way Forward? [REVIEW] Science and Engineering Ethics 9 (1):3-16.
Similar books and articles
Shaili Jain (2007). Understanding Physician-Pharmaceutical Industry Interactions. Cambridge University Press.
Martin Kenney (1987). The Ethical Dilemmas of University-Industry Collaborations. Journal of Business Ethics 6 (2):127 - 135.
Raymond Spier (1995). Ethical Aspects of the University-Industry Interface. Science and Engineering Ethics 1 (2):151-162.
Alison M. Jaggar (2007). Teaching in Colorado: Not a Rocky Mountain High; Academic Freedom in a Climate of Repression. Teaching Philosophy 30 (2):149-172.
Alison M. Jaggar (2007). Teaching in Colorado. Teaching Philosophy 30 (2):149-172.
Nancy F. Olivieri (2003). Patients' Health or Company Profits? The Commercialisation of Academic Research. Science and Engineering Ethics 9 (1):29-41.
Jason Borenstein & Yvette E. Pearson (2008). Taking Conflicts of Interest Seriously Without Overdoing It: Promises and Perils of Academic-Industry Partnerships. [REVIEW] Journal of Academic Ethics 6 (3):229-243.
Richard T. De George (2003). Ethics, Academic Freedom and Academic Tenure. Journal of Academic Ethics 1 (1):11-25.
Robert Streiffer (2006). Academic Freedom and Academic-Industry Relationships in Biotechnology. Kennedy Institute of Ethics Journal 16 (2):129-149.
Christina Lux (2002). Conflicts of Interest in Germany: A Legal Perspective. Science and Engineering Ethics 8 (3):327-336.
Added to index2009-01-28
Total downloads4 ( #267,530 of 1,101,833 )
Recent downloads (6 months)1 ( #306,516 of 1,101,833 )
How can I increase my downloads?